40 Myeloproliferative disorders + CML Flashcards

1
Q

Name the three myeloproliferative disorders.

A

Polycthaemia vera.
Essential thrombocytosis.
Idiopathic fibrosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the blood abnormality in polycythaemia vera?

A

Increased RBCs ± increased neutrophils and platelets.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the clinical features of polycythaemia vera? (8).

A
Insidious.
Itching. 
Plethoric face.
Headache and general malaise.
Tinnititus.
Peptic ulcer.
Gout.
Engorged retinal veins.
Splenomegaly.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which tests are used to distinguish between the different types of polycythaemia? (4).

A

FBC.
Ferritin.
Epo (erythropoietin) level.
U&Es/LFTs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How is 1o polycythaemia differentiated from 2o?

A

1o: RBC production with low EPO.
2o: EPO raised.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Name five causes of secondary polycythaemia:

A
Any central hypoxic process.
Renal disease.
EPO producing tumour.
Drug associated (androgens, post renal transplant).
Congenital.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which tests should be done in polycythaemia vera? (3).

A

JAK2 mutation.
Bone marrow examination.
EXON12 mutation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the JAK2 mutation?
Nucleotide?
Amino acid?
Mechanism?

A

In JH2 domain (inactive).
G-T mutation at nucleotide 1849.
V617F (phenylalanine for valine ar 617).
Destroys BsaXI site.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What does the JAK2 mutation do? (2)

A

Promotes cell division.

EPO no longer needed to turn on EPO receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the JAK2 mutation diagnostic of?

A

A myeloproliferative disorder.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the treatment for polycythaemia vera?
Risks?
Survival?

A

Venesection, aspirin.
Progression to AML and myelofibrosis.
15 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is thrombocytosis?

A

Increased platelets.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the causes of thrombocytosis?

A

1o: essential.
2o: reactive (surgery, infection, malignancy, low iron, hyposplenism, haemolysis, drug).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the 1st and 2nd line investigations for thrombocytosis?

A

1: Blood film, ferritin,CRP, CXR, ESR.
2: JAK and CALR mutations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the CALR mutation?
What does it do?
Who is it found in?

A

Calreticulin mutation in exon 9 of gene.
Activates cell signalling pathways.
+ve in 90% of JAK2 -ve essential thrmobocytosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How is essential thrombocyosis treated? (1,4)

Survivial?

A

Aspirin.
If high thrombotic risk then cytoreduction: hydroxycarbamide, interferon, anagrelide, P32.
20 years.

17
Q

How does myelofibrosis present? (5)

A

Pancytopoenia.
B symptoms: night sweats, fever, weight loss.
Massive splenomegaly.

18
Q

How is myelofibrosis diagnosed? (3)

A

Blood film.
Bone marrow results.
JAK2/CALR mutation.

19
Q

What is the treatment and prognosis of myelofibrosis?

A

Supportive, JAK2 inhibitors, BM transplant.

Poor - 5 year median survival.

20
Q

Who gets chronic myeloid leukaemia?

A

55-60y/o.

M 1.5 : 1 F

21
Q

What are the characteristics of CML? (4).

A

Leucocytosis.
Leucoerythroblastic blood film.
Anaemia.
Splenomegaly.

22
Q

What are the symptoms of CML? (4).

A

Abdominal pain.
Fatigue from anaemia.
Venous occlusion: retinal, DVT, priapism.
Gout.

23
Q

What is the common genetic defect in CML?

A

BCR-ABL fusion gene coding for active tyrosine kinase.

Philadelphia chromosome. 9:22 translocation.

24
Q

Which drug is used in CML?

How does it work?

A

Gleevec (imatinib).

Blocks active site of bcr-abl tyrosine kinase.

25
Q

How does imatinib resistance occur?

New treatment? (2)

A

Activating loop mutations in BCR-ABL.

Nilotinib, Dasatinib.

26
Q

Differentiate between CML and CLL.

A

CML: Leucocytosis.
CLL: Leucocytosis of which 99% are B cells.

27
Q

What is the clinical course of CLL? (2)

Rx? (3)

A

Most commonly occurs in older patients who die of other diseases.
In young, more aggressive - treat with fludarabine, cyclophosphamide and rituximab.

28
Q

What is the prognosis with imatinib treated CML?

A

95% 5 year survival.